Literature DB >> 12803168

Risk for fracture in women with low serum levels of thyroid-stimulating hormone.

D C Bauer1, B Ettinger, M C Nevitt, K L Stone.   

Abstract

BACKGROUND: Biochemical evidence of hyperthyroidism may be associated with low bone mass, particularly in older postmenopausal women, but no prospective studies of thyroid function and subsequent fracture risk have been done.
OBJECTIVE: To examine the association between low levels of thyroid-stimulating hormone (TSH) and fracture in older women.
DESIGN: Prospective cohort study with case-cohort sampling.
SETTING: Four clinical centers in the United States. PATIENTS: 686 women older than 65 years of age from a cohort of 9704 women recruited from population-based listings between 1986 and 1988. MEASUREMENTS: Baseline assessment of calcaneal bone mass, spine radiography, and history of thyroid disease. Spine radiography was repeated after a mean follow-up of 3.7 years; nonspine fractures were centrally adjudicated. Thyroid-stimulating hormone was measured in sera obtained at baseline from 148 women with new hip fractures, 149 women with new vertebral fractures, and a subsample of 398 women randomly selected from the cohort.
RESULTS: After adjustment for age, history of previous hyperthyroidism, self-rated health, and use of estrogen and thyroid hormone, women with a low TSH level (0.1 mU/L) had a threefold increased risk for hip fracture (relative hazard, 3.6 [95% CI, 1.0 to 12.9]) and a fourfold increased risk for vertebral fracture (odds ratio, 4.5 [CI, 1.3 to 15.6]) compared with women who had normal TSH levels (0.5 to 5.5 mU/L). After adjustment for TSH level, a history of hyperthyroidism was associated with a twofold increase in hip fracture (relative hazard, 2.2 [CI, 1.0 to 4.4]), but use of thyroid hormone itself was not associated with increased risk for hip fracture (relative hazard, 0.5 [CI, 0.2 to 1.3]).
CONCLUSIONS: Women older than 65 years of age who have low serum TSH levels, indicating physiologic hyperthyroidism, are at increased risk for new hip and vertebral fractures. Use of thyroid hormone itself does not increase risk for fracture if TSH levels are normal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12803168     DOI: 10.7326/0003-4819-134-7-200104030-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  107 in total

Review 1.  Well differentiated thyroid carcinoma: current treatment.

Authors:  J Kenneth Byrd; Robert J Yawn; Christina S T Wilhoit; Nicoleta D Sora; Linda Meyers; Jyotika Fernandes; Terry Day
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 2.  The role of FSH and TSH in bone loss and its clinical relevance.

Authors:  Manasi Agrawal; Guangyu Zhu; Li Sun; Mone Zaidi; Jameel Iqbal
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

3.  Thyroid gland: Variation in 'normal' thyroid function--effect on bone health?

Authors:  Mark S Cooper
Journal:  Nat Rev Endocrinol       Date:  2010-11       Impact factor: 43.330

Review 4.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

5.  Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism.

Authors:  Islam R Younis; Mariam A Ahmed; Kenneth D Burman; Offie P Soldin; Jacqueline Jonklaas
Journal:  Thyroid       Date:  2018-01-02       Impact factor: 6.568

Review 6.  Actions of pituitary hormones beyond traditional targets.

Authors:  Mone Zaidi; Maria I New; Harry C Blair; Alberta Zallone; Ramkumarie Baliram; Terry F Davies; Christopher Cardozo; James Iqbal; Li Sun; Clifford J Rosen; Tony Yuen
Journal:  J Endocrinol       Date:  2018-03-19       Impact factor: 4.286

7.  The value of laboratory tests in diagnosing secondary osteoporosis at a fracture and osteoporosis outpatient clinic.

Authors:  Gijs de Klerk; J Han Hegeman; Detlef van der Velde; Job van der Palen; Leo van Bergeijk; Henk J Ten Duis
Journal:  Geriatr Orthop Surg Rehabil       Date:  2013-06

8.  [Osteoporosis--which therapy is confirmed?].

Authors:  P M Jehle; J Pfeilschifter
Journal:  Internist (Berl)       Date:  2009-12       Impact factor: 0.743

Review 9.  Subclinical hyperthyroidism: to treat or not to treat?

Authors:  E H Hoogendoorn; M den Heijer; A P J van Dijk; A R Hermus
Journal:  Postgrad Med J       Date:  2004-07       Impact factor: 2.401

10.  Variation in risk factors for fractures at different sites.

Authors:  Jennifer L Kelsey; Elizabeth J Samelson
Journal:  Curr Osteoporos Rep       Date:  2009-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.